We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
SELLAS Life Sciences Group Inc | NASDAQ:SLS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.015 | 1.11% | 1.37 | 1.37 | 1.38 | 1.4197 | 1.33 | 1.37 | 679,379 | 23:52:42 |
As filed with the Securities and Exchange Commission on May 12, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SELLAS Life Sciences Group, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 20-8099512 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
7 Times Square, Suite 2503,
New York, NY 10036
(Address, including zip code, of registrant’s principal executive offices)
SELLAS Life Sciences Group, Inc. 2019 Equity Incentive Plan
(Full Title of the Plan)
Angelos M. Stergiou, M.D., Sc.D. h.c.
President and Chief Executive Officer
SELLAS Life Sciences Group, Inc.
7 Times Square, Suite 2503, New York, NY 10036
Telephone: (646) 200-5278
(Name, address, and telephone number, including area code, of agent for service)
Copies to:
Joel I. Papernik, Esq.
Daniel A. Bagliebter, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
666 Third Avenue New York, NY 10017 (212) 935-3000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ¨ | Accelerated filer | ¨ | ||
Non-accelerated filer | x | Smaller reporting company | x | ||
Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This registration statement registers an aggregate of 794,782 additional shares of common stock, par value $0.0001 per share (“common stock”), of SELLAS Life Sciences Group, Inc. (the “Registrant”) reserved under the 2019 Equity Incentive Plan (the “Plan”), representing an increase of 794,782 shares reserved under the Plan effective January 1, 2022 by operation of the Plan’s “evergreen” provision. This registration statement registers additional securities of the same class as other securities for which registration statements filed on Form S-8 (File Nos. 333-237168 and 333-258799) relating to an employee benefit plan are effective. The information contained in the Registrant’s registration statements on Form S-8 filed with the Securities and Exchange Commission on March 13, 2020 (File No. 333-237168) and August 13, 2021 (File No. 333-258799) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.
2
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
+ Denotes management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York, on May 12, 2022.
SELLAS LIFE SCIENCES GROUP, INC. | ||
By: | /s/ Angelos M. Stergiou | |
Angelos M. Stergiou, M.D., ScD h.c. | ||
President and Chief Executive Officer |
Each person whose signature appears below constitutes and appoints each of Angelos M. Stergiou and Barbara A. Wood, acting alone or together with another attorney-in-fact, as his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.
Signature | Title | Date | ||
/s/ Angelos M. Stergiou | President, Chief Executive Officer and Director (Principal Executive Officer and Principal Financial Officer) |
May 12, 2022 | ||
Angelos M. Stergiou, M.D., ScD h.c. | ||||
/s/ John T. Burns | Senior Vice President, Finance and Chief Accounting
Officer (Principal Accounting Officer) |
May 12, 2022 | ||
John T. Burns, CPA | ||||
/s/ Jane Wasman | Chair of the Board of Directors | May 12, 2022 | ||
Jane Wasman | ||||
/s/ David Scheinberg | Director | May 12, 2022 | ||
David Scheinberg, M.D., PhD. | ||||
/s/ Robert Van Nostrand | Director | May 12, 2022 | ||
Robert Van Nostrand | ||||
/s/ John Varian | Director | May 12, 2022 | ||
John Varian |
1 Year SELLAS Life Sciences Chart |
1 Month SELLAS Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions